Disease-in-A-dish: The contribution of patient-specific induced pluripotent stem cell technology to regenerative rehabilitation

American Journal of Physical Medicine and Rehabilitation

Volumn 93, Issue 11, 2014, Pages S155-S168

  Mack, David L ^a   Guan, Xuan ^a,b,c   Wagoner, Ashley ^c   Walker, Stephen J ^c   Childers, Martin K ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Autism; Cardiomyopathy; Disease in a dish; Disease modeling; Drug screening; Duchenne muscular dystrophy; Induced pluripotent stem cells; Neuromuscular diseases

Indexed keywords

ANIMAL; BIOENGINEERING; DRUG DEVELOPMENT; FORECASTING; HUMAN; NEUROMUSCULAR DISEASES; NUCLEAR REPROGRAMMING; PERSONALIZED MEDICINE; PLURIPOTENT STEM CELL; PROCEDURES; REGENERATIVE MEDICINE; REHABILITATION MEDICINE; STEM CELL TRANSPLANTATION; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME; TRENDS;

ANIMALS; BIOENGINEERING; CELLULAR REPROGRAMMING; DRUG DISCOVERY; FORECASTING; HUMANS; INDIVIDUALIZED MEDICINE; INDUCED PLURIPOTENT STEM CELLS; NEUROMUSCULAR DISEASES; PHYSICAL AND REHABILITATION MEDICINE; QUALITY IMPROVEMENT; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84914816525     PISSN: 08949115     EISSN: 15377385     Source Type: Journal    
DOI: 10.1097/PHM.0000000000000141     Document Type: Article

References (123)

1. Puri MC, Nagy A: Concise review: Embryonic stem cells versus induced pluripotent stem cells: The game is on. Stem Cells 2012;30:10-4
2. Ogawa M: Differentiation and proliferation of hematopoietic stem cells. Blood 1993;81:2844-53
3. Seita J, Weissman IL: Hematopoietic stem cell: Self-renewal versus differentiation. Wiley Interdiscip Rev Syst Biol Med 2010;2:640-53
4. Thomas ED: Bone marrow transplantation from the personal viewpoint. Int J Hematol 2005;81:89-93
5. Vaughan W, Seshadri T, Bridges M, et al: The principles and overview of autologous hematopoietic stem cell transplantation. Cancer Treat Res 2009;144:23-45
6. Prockop DJ: Repair of tissues by adult stem/progenitor cells (MSCs): Controversies, myths, and changing paradigms. Mol Ther 2009;17:939-46
7. Caplan AI: Why are MSCs therapeutic? New data: New insight. J Pathol 2009;217:318-24
8. Wagner J, et al: Optimizing mesenchymal stem cellYbased therapeutics. Curr Opin Biotechnol 2009;20:531-6
9. Hass R, et al: Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal 2011;9:12
10. Trounson A, et al: Clinical trials for stem cell therapies. BMC Med 2011;9:52
11. Karp JM, Leng Teo GS: Mesenchymal stem cell homing: The devil is in the details. Cell Stem Cell 2009;4:206-16
12. Kean TJ, et al: MSCs: Delivery Routes and Engraftment, Cell-Targeting Strategies, and Immune Modulation. Stem Cells Int 2013;2013:732742
13. Digirolamo CM, et al: Propagation and senescence of human marrow stromal cells in culture: A simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate. Br J Haematol 1999;107:275-81
14. Estrada JC, et al: Human mesenchymal stem cellreplicative senescence and oxidative stress are closely linked to aneuploidy. Cell Death Dis 2013;4:e691
15. Ambrosio F, Russell A: Regenerative rehabilitation: A call to action. J Rehabil Res Dev 2010;47:xi-xv
16. Takahashi K, Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-76
17. Doi A, et al: Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet 2009;41:1350-3
18. Takahashi K, et al: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-72
19. Yu J, et al: Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318:1917-20
20. Park IH, et al: Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008;451:141-6
21. Hacein-Bey-Abina S, et al: LMO2-Associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003;302:415-9
22. Cyranoski D: Stem cells: 5 things to know before jumping on the iPS bandwagon. Nature 2008;452:406-8
23. Guan X, et al: Dystrophin-deficient cardiomyocytes derived from human urine: New biologic reagents for drug discovery. Stem Cell Res 2013;12:467-80
24. Burelle Y, et al: Alterations in mitochondrial function as a harbinger of cardiomyopathy: Lessons from the dystrophic heart. J Mol Cell Cardiol 2010;48:310-21
25. Yilmaz A, Sechtem U: Cardiac involvement in muscular dystrophy: Advances in diagnosis and therapy. Heart 2012;98:420-9
26. Horvath K, et al: Gastrointestinal abnormalities in children with autistic disorder. J Pediatr 1999;135:559-63
27. Dawson G, et al: Randomized, controlled trial of an intervention for toddlers with autism: The Early Start Denver Model. Pediatrics 2010;125:e17-23
28. Kohane IS, et al: The co-morbidity burden of children and young adults with autism spectrum disorders. PLoS One 2012;7:e33224
29. Ming X, et al: Autism spectrum disorders and identified toxic land fills: Co-occurrence across States. Environ Health Insights 2008;2:55-9
30. Valicenti-McDermott M, et al: Frequency of gastrointestinal symptoms in children with autistic spectrum disorders and association with family history of autoimmune disease. J Dev Behav Pediatr 2006;27(suppl):S128-36
31. Buie T, et al: Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: A consensus report. Pediatrics 2010;125(suppl):S1-18
32. Wang LW, Tancredi DJ, Thomas DW: The prevalence of gastrointestinal problems in children across the United States with autism spectrum disorders from families with multiple affected members. J Dev Behav Pediatr 2011;32:351-60
33. Chaidez V, Hansen RL, Hertz-Picciotto I: Gastrointestinal problems in children with autism, developmental delays or typical development. J Autism Dev Disord 2014;44:1117-27
34. Ibrahim SH, et al: Incidence of gastrointestinal symptoms in children with autism: A populationbased study. Pediatrics 2009;124:680-6
35. De Magistris L, et al: Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. J Pediatr Gastroenterol Nutr 2010;51:418-24
36. Finegold SM: Desulfovibrio species are potentially important in regressive autism. Med Hypotheses 2011;77:270-4
37. Finegold SM, et al: Gastrointestinal microflora studies in late-onset autism. Clin Infect Dis 2002;35(suppl):S6-16
38. Buie T, et al: Recommendations for evaluation and treatment of common gastrointestinal problems in children with ASDs. Pediatrics 2010;125(suppl):S19-29
39. Emanuele E, et al: Low-grade endotoxemia in patients with severe autism. Neurosci Lett 2010;471:162-5
40. Adams JB, et al: Gastrointestinal flora and gastrointestinal status in children with autismVComparisons to typical children and correlation with autism severity. BMC Gastroenterol 2011;11:22
41. Pennesi CM, Klein LC: Effectiveness of the glutenfree, casein-free diet for children diagnosed with autism spectrum disorder: Based on parental report. Nutr Neurosci 2012;15:85-91
42. Sandler RH, et al: Short-term benefit from oral vancomycin treatment of regressive-onset autism. J Child Neurol 2000;15:429-35
43. Anderson RB, Stewart AL, Young HM: Phenotypes of neural-crest-derived cells in vagal and sacral pathways. Cell Tissue Res 2006;323:11-25
44. Berthoud HR, et al: Neuroanatomy of extrinsic afferents supplying the gastrointestinal tract. Neurogastroenterol Motil 2004;16(suppl):28-33
45. Sanders KM, Koh SD, Ward SM: Interstitial cells of cajal as pacemakers in the gastrointestinal tract. Annu Rev Physiol 2006;68:307-43
46. Taylor CT, Keely SJ: The autonomic nervous system and inflammatory bowel disease. Auton Neurosci 2007;133:104-14
47. Torrente F, et al: Small intestinal enteropathy with epithelial IgG and complement deposition in children with regressive autism. Mol Psychiatry 2002;7:375-82, 334
48. Arons MH, et al: Autism-Associated mutations in ProSAP2/Shank3 impair synaptic transmission and neurexin-neuroliginYmediated transsynaptic signaling. J Neurosci 2012;32:14966-78
49. Baudouin SJ, et al: Shared synaptic pathophysiology in syndromic and nonsyndromic rodent models of autism. Science 2012;338:128-32
50. Chubykin AA, et al: Dissection of synapse induction by neuroligins: Effect of a neuroligin mutation associated with autism. J Biol Chem 2005;280:22365-74
51. Durand CM, et al: SHANK3 mutations identified in autism lead to modification of dendritic spine morphology via an actin-dependent mechanism. Mol Psychiatry 2012;17:71-84
52. Gilman SR, et al: Rare de novo variants associated with autism implicate a large functional network of genes involved in formation and function of synapses. Neuron 2011;70:898-907
53. Hussman JP, et al: A noise-reduction GWAS analysis implicates altered regulation of neurite outgrowth and guidance in autism. Mol Autism 2011;2:1
54. Moessner R, et al: Contribution of SHANK3 mutations to autism spectrum disorder. Am J Hum Genet 2007;81:1289-97
55. State MW, Levitt P: The conundrums of understanding genetic risks for autism spectrum disorders. Nat Neurosci 2011;14:1499-506
56. Sudhof TC: Neuroligins and neurexins link synaptic function to cognitive disease. Nature 2008;455:903-11
57. Anderlid BM, et al: FISH-mapping of a 100-kb terminal 22q13 deletion. Hum Genet 2002;110:439-43
58. Betancur C, Buxbaum JD: SHANK3 haploinsufficiency: A Bcommon[but underdiagnosed highly penetrant monogenic cause of autism spectrum disorders. Mol Autism 2013;4:17
59. Boccuto L, et al: Prevalence of SHANK3 variants in patients with different subtypes of autism spectrum disorders. Eur J Hum Genet 2013;21:310-6
60. Bonaglia MC, et al: Identification of a recurrent breakpoint within the SHANK3 gene in the 22q13.3 deletion syndrome. J Med Genet 2006;43:822-8
61. Durand CM, et al: Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet 2007;39:25-7
62. Gauthier J, et al: Novel de novo SHANK3 mutation in autistic patients. Am J Med Genet B Neuropsychiatr Genet 2009;150B:421-4
63. Schaaf CP, et al: Oligogenic heterozygosity in individuals with high-functioning autism spectrum disorders. Hum Mol Genet 2011;20:3366-75
64. Wilson HL, et al: Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms. J Med Genet 2003;40:575-84
65. Phelan K, McDermid HE: The 22q13.3 deletion syndrome (Phelan-McDermid syndrome). Mol Syndromol 2012;2:186-201
66. Soorya L, et al: Prospective investigation of autism and genotype-phenotype correlations in 22q13 deletion syndrome and SHANK3 deficiency. Mol Autism 2013;4:18
67. Tiscornia G, Vivas EL, Izpisua Belmonte JC: Diseases in a dish: Modeling human genetic disorders using induced pluripotent cells. Nat Med 2011;17:1570-6
68. Ebert AD, et al: Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009;457:277-80
69. Itzhaki I, et al: Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011;471:225-9
70. Zhou T, et al: Generation of human induced pluripotent stem cells from urine samples. Nat Protoc 2012;7:2080-9
71. Zhou T, et al: Generation of induced pluripotent stem cells from urine. J Am Soc Nephrol 2011;22:1221-8
72. Zhang Y, et al: Urine derived cells are a potential source for urological tissue reconstruction. J Urol 2008;180:2226-33
73. Guenther MG, et al: Chromatin structure and gene expression programs of human embryonic and induced pluripotent stemcells. Cell Stem Cell 2010;7:249-57
74. Lister R, et al: Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011;471:68-73
75. Meissner A: Epigenetic modifications in pluripotent and differentiated cells. Nat Biotechnol 2010;28:1079-88
76. Kim K, et al: Epigenetic memory in induced pluripotent stem cells. Nature 2010;467:285-90
77. Polo JM, et al: Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol 2010;28:848-55
78. Li H, et al: Spontaneous expression of embryonic factors and p53 point mutations in aged mesenchymal stem cells: A model of age-related tumorigenesis in mice. Cancer Res 2007;67:10889-98
79. Bork S, et al: DNA methylation pattern changes upon long-term culture and aging of human mesenchymal stromal cells. Aging Cell 2010;9:54-63
80. Mayshar Y, et al: Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 2010;7:521-31
81. Gore A, et al: Somatic coding mutations in human induced pluripotent stem cells. Nature 2011;471:63-7
82. Hussein SM, et al: Copy number variation and selection during reprogramming to pluripotency. Nature 2011;471:58-62
83. Laurent LC, et al: Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 2011;8:106-18
84. Osafune K, et al: Marked differences in differentiation propensity among human embryonic stem cell lines. Nat Biotechnol 2008;26:313-5
85. Irion S, et al: Directed differentiation of pluripotent stem cells: From developmental biology to therapeutic applications. Cold Spring Harb Symp Quant Biol 2008;73:101-10
86. Murry CE, Keller G: Differentiation of embryonic stem cells to clinically relevant populations: Lessons from embryonic development. Cell 2008;132:661-80
87. Laflamme MA, et al: Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 2007;25:1015-24
88. Kim DH, et al: Matrix nanotopography as a regulator of cell function. J Cell Biol 2012;197:351-60
89. Kim HN, et al: Nanotopography-guided tissue engineering and regenerative medicine. Adv Drug Deliv Rev 2013;65:536-58
90. Kshitiz G, et al: Matrix rigidity controls endothelial differentiation and morphogenesis of cardiac precursors. Sci Signal 2012;5:ra41
91. Kshitiz, et al: Control of stem cell fate and function by engineering physical microenvironments. Integr Biol (Camb) 2012;4(9):1008-18
92. Distefano G, et al: Neuromuscular electrical stimulation as a method to maximize the beneficial effects of muscle stem cells transplanted into dystrophic skeletal muscle. PLoS One 2013;8:e54922
93. Raghavan S, et al: Successful implantation of bioengineered, intrinsically innervated, human internal anal sphincter. Gastroenterology 2011;141:310-9
94. Adams JE 3rd, et al: Cardiac troponin I. A marker with high specificity for cardiac injury. Circulation 1993;88:101-6
95. Hoogerwaard EM, et al: Troponin T and troponin I in carriers of Duchenne and Becker muscular dystrophy with cardiac involvement. Clin Chem 2001;47:962-3
96. Ramaciotti C, Iannaccone ST, Scott WA: Myocardial cell damage in Duchenne muscular dystrophy. Pediatr Cardiol 2003;24:503-6
97. Townsend D, et al: Chronic administration of membrane sealant prevents severe cardiac injury and ventricular dilatation in dystrophic dogs. J Clin Invest 2010;120:1140-50
98. Allen DG, Zhang BT, Whitehead NP: Stretch-induced membrane damage in muscle: Comparison of wildtype and mdx mice. Adv Exp Med Biol 2010;682:297-313
99. Childers MK, et al: Eccentric contraction injury in dystrophic canine muscle. Arch Phys Med Rehabil 2002;83:1572-8
100. Childers MK, et al: Myofiber injury and regeneration in a canine homologue of Duchennemuscular dystrophy. Am J Phys Med Rehabil 2001;80:175-81
101. Childers MK, et al: Skinned single fibers from normal and dystrophin-deficient dogs incur comparable stretch-induced force deficits. Muscle Nerve 2005;31:768-71
102. De Pooter J, et al: Elevated troponin T levels in a female carrier of Duchenne muscular dystrophy with normal coronary angiogram: A case report and review of the literature. Acta Cardiol 2012;67:253-6
103. Deconinck N, Dan B: Pathophysiology of Duchenne muscular dystrophy: Current hypotheses. Pediatr Neurol 2007;36:1-7
104. Grounds MD: Two-tiered hypotheses for Duchenne muscular dystrophy. Cell Mol Life Sci 2008;65(11):1621-5
105. Phillips MF, Quinlivan R: Calcium antagonists for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008:CD004571
106. Perel P, et al: Comparison of treatment effects between animal experiments and clinical trials: Systematic review. BMJ 2007;334:197
107. Dimos JT, et al: Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008;321:1218-21
108. Lee G, et al: Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 2009;461:402-6
109. Marchetto MC, et al: A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 2010;143:527-39
110. Farra N, et al: Rett syndrome induced pluripotent stem cell-derived neurons reveal novel neurophysiological alterations. Mol Psychiatry 2012;17:1261-71
111. Brennand KJ, et al: Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011;473:221-5
112. Wernig M, et al: Neurons derived fromreprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci USA 2008;105:5856-61
113. Pasca SP, et al: Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome. Nat Med 2011;17:1657-62
114. Yazawa M, et al: Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 2011;471:230-4
115. Salva MZ, et al: Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Mol Ther 2007;15 (2) 320-9
116. Pharmaceutical Research and Manufacturers of America Profile. Washington, DC, PhRMA, 2009
117. Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov 2010;9:89-92
118. Holland J: Fixing a broken drug development process. J Commercial Biotechnol 2013;19:5-6
119. Fitz Gerald GA: Re-engineering drug discovery and development. LDI Issue Brief 2011;17:1-4
120. Zhou H, et al: Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009;4:381-4
121. Kim D, et al: Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009;4:472-6
122. Warren L, et al: Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010;7:618-30
123. Obokata H, et al: Stimulus-triggered fate conversion of somatic cells into pluripotency. Nature 2014;505:641-7